AU2016204324A1 - Antibody formulation - Google Patents
Antibody formulationInfo
- Publication number
- AU2016204324A1 AU2016204324A1 AU2016204324A AU2016204324A AU2016204324A1 AU 2016204324 A1 AU2016204324 A1 AU 2016204324A1 AU 2016204324 A AU2016204324 A AU 2016204324A AU 2016204324 A AU2016204324 A AU 2016204324A AU 2016204324 A1 AU2016204324 A1 AU 2016204324A1
- Authority
- AU
- Australia
- Prior art keywords
- formulation
- antibody formulation
- methods
- antibody
- ghmatters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Abstract
The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior 5 lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation. 7899286_1 (GHMatters) P90324.AU.2
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016204324A AU2016204324A1 (en) | 2009-12-21 | 2016-06-24 | Antibody formulation |
AU2017279638A AU2017279638A1 (en) | 2009-12-21 | 2017-12-20 | Antibody formulation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/288,535 | 2009-12-21 | ||
AU2013202276A AU2013202276B2 (en) | 2009-12-21 | 2013-04-02 | Antibody formulation |
AU2016204324A AU2016204324A1 (en) | 2009-12-21 | 2016-06-24 | Antibody formulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013202276A Division AU2013202276B2 (en) | 2009-12-21 | 2013-04-02 | Antibody formulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017279638A Division AU2017279638A1 (en) | 2009-12-21 | 2017-12-20 | Antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2016204324A1 true AU2016204324A1 (en) | 2016-07-14 |
Family
ID=56682824
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016204324A Abandoned AU2016204324A1 (en) | 2009-12-21 | 2016-06-24 | Antibody formulation |
AU2017279638A Abandoned AU2017279638A1 (en) | 2009-12-21 | 2017-12-20 | Antibody formulation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017279638A Abandoned AU2017279638A1 (en) | 2009-12-21 | 2017-12-20 | Antibody formulation |
Country Status (1)
Country | Link |
---|---|
AU (2) | AU2016204324A1 (en) |
-
2016
- 2016-06-24 AU AU2016204324A patent/AU2016204324A1/en not_active Abandoned
-
2017
- 2017-12-20 AU AU2017279638A patent/AU2017279638A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2017279638A1 (en) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY159156A (en) | Antibody formulation | |
AR124140A2 (en) | ANTIBODY FORMULATIONS | |
MX2009006594A (en) | Formulations. | |
MX2012007684A (en) | Ligand-directed covalent modification of protein. | |
TNSN08511A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
AR097791A1 (en) | ANTI-PDL1 ANTIBODY FORMULATIONS | |
NZ708103A (en) | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment | |
MX2019006633A (en) | Antibody formulations. | |
TN2009000382A1 (en) | Stable antibody formulations | |
EA200802170A1 (en) | LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY | |
TN2012000023A1 (en) | Subcutaneous anti-her2 antibody formulation | |
WO2007095337A3 (en) | Antibody formulation | |
MX2010008035A (en) | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof. | |
PE20181790A1 (en) | METHODS TO TREAT OR PREVENT CHOLESTEROL-RELATED DISORDERS | |
NZ599176A (en) | Immunoconjugate formulations | |
NZ605873A (en) | Methods and compositions for cns delivery of arylsulfatase a | |
PH12019501796A1 (en) | Low ph pharmaceutical composition comprising t cell engaging antibody constructs | |
WO2012003470A3 (en) | Antibody formulations | |
EP4219560A3 (en) | Integrin alpha v beta 8 neutralizing antibody | |
MX2017003121A (en) | Antibody formulations. | |
WO2007106915A3 (en) | Antibodies to egfl7 and methods for their use | |
MX2007010930A (en) | Formulation for aviptadil. | |
WO2013006766A3 (en) | Formulations that stabilize proteins | |
AU2016204324A1 (en) | Antibody formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |